EPFL: École Polytechnique Fédérale de Lausanne (Switzerland) From its foundation in 1853, the **EPFL** has evolved into a topranked research and teaching institution attracting some of the best researchers and professors in the world. Nearly 10,000 people from 110 nations share this campus

 IEEE
 SENSORS 2013

 Tutorials: November 3, 2013
 Conference: November 4-6, 2013

Baltimore, November 3rd, 2013

Tutorial Technologies for an Implantable Nano-Bio-Sensing Laboratory

SANDRO CARRARA

ÉCOLE POLYTECHNIQUE Laboratoire des Systèmes Intégrés (LSI) FÉDÉRALE DE LAUSANNE

Different outcomes for different patients

Cancer (all



norapoutto aroa	hate of emcacy with standard drug treatment
Cancer (all types)	25%
heimer's disease	30%
Incontinence	40%
Hepatitis C	47%
Osteoporosis	48%
umatoid arthritis	50%
aine (prophylaxis)	50%
Migraine (acute)	52%
Diabetes	57%
Asthma	60%
diac arrhythmias	60%
Schizophrenia	60%
Depression	62%

of office cy with standard drug treatment

For depression, the data apply specifically to the drug class known as selective serotonin reuptake inhibitors

Source: Brian B. Spear, Margo Heath-Chiozzi, and Jeffrey Huff, "Clinical Application of Pharmacogenetics," Trends in Molecular Medicine (May 2001)

System Biology is not enough



(c) S.Carrara, EPFL (Switzerland)

Personalized Therapy



Development of Monitoring Point-of-Care Devices is a key-factor for succeeding in Personalized Therapy (c) S.Carrara, EPFL (Switzerland)



⁽c) S.Carrara, EPFL (Switzerland)

Personalized Therapy and I.M.D.



is a key-factor for succeeding in Personalized therapy

Fully Connected Human++



State-of-the-Art is limited

A. Menarini GlucoMenDay

Abbott FreeStyle Navigator



Dexcom SEVEN Plus

Medtronic MiniMed Guardian

Continuous Monitoring Systems typically consist of a biosensor coupled with a microdialysis sampling system

Multi-Panel Platforms for Human Metabolism



P450 for Drugs Monitoring



Problems on Detection Limits



Detection of verapamil by 3A4, an antihypertensive drug, was from 400 μ M to 3mM while its therapeutic range is below 0.3 μ M

An improved P450/Electrode coupling by using Carbon Nanotubes



Nano-Bio-Sensors integration

BARE ELECTRODE





Boero, Carrara et al. / IEEE PRIME 2009 Boero, Carrara et al. / IEEE ICME 2010 De Venuto, al. et Carrara / IEEE Senors 2010 Boero, Carrara et al. / Sensors & Actuators B 2011 Carrara et al. / Biosensors and Bioelectronics 2011 Boero, Carrara et al. / IEEE T on NanoBioScience 2011 CARBON NANOTUBES 10.3 ± 1.14 nm CNTS + PROBE ENZYMES

3.6 nm

4.9 nm

5.2 nm

19.9 ± 3.38 nm

Acc.V Spot Magn Det WD Ex 1.70 kV 2.0 100000x TLD 2.0 1

(c) S.Carrara, EPFL (Switzerland)

Acc.V

Improved Detection Limit

S. Carrara et al. / Biosensors and Bioelectronics 26 (2011) 3914-3919



Cyclophosphamide (CP), an anti-cancer agent, is detected by P450 3A4 in its therapeutic range

Detection of Several Drugs

C. Bay-Rossi, G. De Micheli, S. Carrara, Sensors 2012, 12, 6520-6537

Drugs	Pharmacologic	al P450	Sensitivity (nA/µM*mm²)		Detection limit (µM)	
			PBS	Serum	PBS	Serum
Cyclophosphamide	3-77	2B6	1	0.3	2	14
Ifosfamide	10-160	3A4	1.6	0.4	2	7
Ftorafur	1-10	1A2	8.8	3.5	0.6	1
Etoposide	34-102	-	74	9	0.05	0.5
	t					
	(c) S.Carrara, EPFL (SERUM			

Breast cancer drugs cocktail

cyclophosphamide, methotrexate, and fluorouracil (CMF)⁽⁸⁾⁽¹¹⁾;
fluorouracil, doxorubicin, and cyclophosphamide (FAC)⁽⁸⁾;
cyclophosphamide, doxorubicin and 5-fluorouracil (CAF)⁽⁹⁾;
fluorouracil, epirubicin, and cyclophosphamide (FEC)⁽⁸⁾⁽¹¹⁾⁽¹²⁾;
fluorouracil, doxorubicin, and cyclophosphamide ⁽¹¹⁾⁽¹²⁾;
flosfamide, Carboplatin, Etoposide (ICE)⁽⁹⁾;
ifosfamide, metho- trexate and 5-fluorouracil (IMF)⁽⁹⁾;

•cyclophosphamide, mitoxantrone, and etoposide⁽¹²⁾.

[8] New England Journal of Medicine, The [0028-4793] Hortobagyi yr:1998 vol:339 iss:14 pg:974 GABRIELN. HORTOBAGYI, M.D.
[9] Cancer Chemother Pharmacol (1999) 44 (Suppl): S26±S28
A.Y. Chang, L. Hui, R. Asbury, L. Boros, G. Garrow, J. Rubins
[10] *Journal of Clinical Oncology*, Vol 22, No 12 (June 15), 2004: pp. 2284-2293
M. Ayers, W.F. Symmans, J. Stec, A.I. Damokosh, E. Clark, K. Hess, et al.
[11] *Journal of Clinical Oncology*, Vol 21, Issue 13 (July), 2003: 2600-2608
Manfred Kaufmann, Gunter von Minckwitz, Roy Smith, Vicente Valero, et al
[12] The Lancet [0140-6736] Weiss yr:2000 vol:355 iss:9208 pg:999 *Raymond B Weiss, Robert M Rifkin, F Marc Stewart, Richard L Theriault, et al.*

Different Drugs give peaks in different positions

Substrate/inhibitor	of CYP2C9	$K_m (\mu \mathbf{M})$	K_i (μ M)	CYP2C9	(mV)	$E_{\rm mid}$ CYP2C9 + substrate (mV)
Torsemide (s) Diclofenac (s) Tolbutamide (s) S-Warfarin (s) Sulfaphenazole (i)		11.4 6.8 120 ^a 6 ^b	0.1 ^c	$-41 \\ -41 \\ -41 \\ -41 \\ -41 \\ -41$		-19 -41 -37 -36 -41
CO _(g)				-41		8

D.L. Johnson et al. / Biochemical Pharmacology 69 (2005) 1533-1541

 $i(V) = i_{C}(V) + \sum_{\forall k} A_{k} e^{-\frac{(V-V_{k})^{2}}{\sigma_{k}^{2}}}$ Charging current

Faradic currents

The cytochrome P450 2C9 presents peak shifts in the range of tens of mV by changing drug substrates

The Heterotropic Kinetics



• HETERO ACTIVATION

• PARTIAL INHIBITION



D2

Multiple drugs detection: CYP3A4



Different amounts of CP and DX result in

two very-well defined peaks once detected by P450 3A4 (c) S.Carrara, EPFL (Switzerland)



Naproxen (NP) and Flurbiprofen (FL) also result in two very-well defined peaks once detected by P450 2C9 (c) S.Carrara, EPFL (Switzerland)

Peaks Amplitude is affected by the other drugs

Substrate/inhibitor o	f CYP2C9	K_m (μ M)	K_i (μ M)	CYP2C9 (mV)	$E_{\rm mid}$ CYP2C9 + substrate (mV)
Torsemide (s)		11.4		-41	-19
Diclofenac (s)		6.8		-41	-41
Tolbutamide (s)		120 ^a		-41	-37
S-Warfarin (s)		6 ^b		-41	-36
Sulfaphenazole (i)	Dereral		0.1°	-41	-41
CO _(g)	Depende	ence from	the other	arug _l concent	rations

D.L. Johnson et al. / Biochemical Pharmacology 69 (2005) 1533-1541

$$i(V) = i_{C}(V) + \sum_{\forall k} \prod_{\forall j \neq k} A_{k} \left(\begin{bmatrix} C_{j} \end{bmatrix} \right)$$

Charging current

Faradic currents

The Gaussian decomposition in cytochrome P450 based detection has to account for the heterotropic kinetics

The Problem of multi-panel arrays response



Multi-Platform design

Four working electrodes differently functionalized



Multiple Calibration Curves



Deal with Calibration Curves Family allow us to improve specificity at system level

Sensors Query in Time



(c) S. Carrara, EPFL (Switzerland) (c) S. Carrara, EPFL (Switzerland)

Multi-Panel Platforms for Human Metabolism





Cottrell Effect

BOERO et al.: HIGHLY SENSITIVE CARBON NANOTUBE-BASED SENSING IEEE TRANSACTIONS ON NANOBIOSCIENCE, VOL. 10, NO. 1, MARCH 2011



(c) S.Carrara, EPFL (Switzerland)

Multi-Panel Platforms for Human Metabolism



ATP detection



Indirect ATP Detection



ATP is detected by a decreasing current at the interface

Indirect ATP Detection



ATP detection is affected by different values of glucose

New Concept in Human Metabolism Telemetry



The design of implantable/wearable systems for continuous monitoring of human metabolism is feasible

Under-the-Skin Device & Wearable Patch



An antenna very close to the chip is required for the remote powering

Under-the-Skin Device



Minimally invasive with size within that of a surgery needle
A reliable system requires:

- 1. CNT-Biochip fully integration
- 2. Precise Current measurements
- 3. Multiplexing for different molecules
- 4. Reliability in Temperature and pH
- 5. Multiplexing Molecular Detection with T and pH
- 6. Reliability for Voltage Sweep
- 7. Remote Powering

A reliable system requires:

- 1. CNT-Biochip fully integration
- 2. Precise Current measurements
- 3. Multiplexing for different molecules
- 4. Reliability in Temperature and pH
- 5. Multiplexing Molecular Detection with T and pH
- 6. Reliability for Voltage Sweep
- 7. Remote Powering

1. Nano-Bio-Sensors Micro-Spotting

Boero, Carrara et al. / IEEE BioCAS 2011 Carbon Nanotubes + Nafion Acc.V Spot Magn Det WD 1 μm 3.00 kV 2.0 20000x TLD 2.9 W3

1b. Nano-Bio-Sensors by Electrodeposition



1b. Nano-Bio-Sensors by Electrodeposition

DROP-CASTING



(c) S.Carrara, EPFL (Switzerland) ELECTRODEPOSITION

1c. Nano-Bio-Sensors by CVD

Integration by Direct Growth



1c. Nano-Bio-Sensors by CVD

Integration by Direct Growth

Results

1.Fe electrodeposition

2.Deposition

- 10 min annealing
- 5 min deposition
- 750 ° C
- 0.25 I/h C₂H₂ flow
- 0.25 I/h CO₂ flow



Nanoparticles Non-compact Compact



1d. Four different techniques



A reliable system requires:

- 1. CNT-Biochip fully integration
- 2. Precise Current measurements
- 3. Multiplexing for different molecules
- 4. Reliability in Temperature and pH
- 5. Multiplexing Molecular Detection with T and pH
- 6. Reliability for Voltage Sweep
- 7. Remote Powering

2. Current Measurements Front-End





Current-to-frequency converter

3. Multiplexing Molecular Detection



4. Reliability in Temperature & pH



(c) S.Carrara, EPFL (Switzerland)

4. Reliability in Temperature & pH



A. Cavallini, al et, S. Carrara / IEEE BioCAS, 2012.

Thin-film technology for pH and Temperature sensors

4. Reliability in pH: OCP vs time



4. Reliability in pH: OCP vs time



Measure of Open Circuit Potential (OCP) vs pH

4. Reliability in T



Measure of the Resistance vs Temperature

5. Multiplexing Molecular detection with T and pH



Figure 8. The bloks-scheme of the multiplexing

The switches also multiplex the T and pH measure

6. Reliability for Voltage Sweep



Sweeping the voltage is definitely required to distinguish each single drug contribution in the Voltammogram

6. Reliability for Voltage Sweep



(c) S.Carrara, EPFL (Switzerland)

al et S. Carrara, et al, IEEE LiSSA 2011

The Chip Frontend; 2nd prototype



 ✓ up to 5 different target detection
 ✓ CV actuation and readout for up to 3

targets with sub μA current

 ✓ CA initiation and readout for up to 2 targets with sub µA current

 Embedded PH and temperature sensing

IC interfaced to the passive platform

S. Carrara et al. / IEEE Sensors Conf. 2012



The IC has been fabricated in UMC 0.18 technology and interfaced to the passive multi-panel platform

The IC Potentiostat



The integrated potentiostat works quite well with respect the well-know and costly lab-one by Autolab

The IC Potentiostat

S.S. Ghoreishizadeh, al., S. Carrara & G. De Micheli / IEEE TBCAS, 2013 submitted



The integrated potentiostat works quite well with respect the well-know and costly lab-one by Autolab

7. Energy Scavenging Strategies



Inductive Coupling

							Distance		
[8]	Tx: 7.8 λ Rx: 1.7 λ	4 MHz	twd Int.: PWM-ASK twd Ext.: ASK	twd Ext.:125 kbps	10 mW		5 mm	Air	Neural Recording System
[9]	Tx: 196.3 λ Rx: 31.4 λ	4 MHz	twd Ext.: LSK	5 kbps	6 mW		25 mm	Water Bearing Colloids	Various
[10]	Tx: 13200 λ Rx: 25.2 λ	1 MHz			150 mW	1% (min)	205 mm	PVC Barrel	Stomach
[11]	Tx: 184.9 λ Rx: 10 λ	1 MHz			10 mW	18.9% (max)	5 mm	Air	Cerebral Cortex
[12]	Tx: 282.7 λ Rx: 31.4 λ	0.7 MHz	twd Int.: ASK twd Ext.: LSK	twd Int.: 60 kbps twd Ext.: 60 kbps	50 mW	36% (max)	30 mm		Orthopaedic Implant
[13]	Tx: 31.4 λ Rx: 5 λ	10 MHz	twd Int.: ASK twd Ext.: BPSK	twd Int.: 120 kbps twd Ext.: 234 kbps	22.5 mW in vitro ≈ 19 mW in vivo		15 mm	Rabbit	Muscles
[14]	Tx: 196.3 λ Rx: 3.5 λ	5 MHz	twd Int.: OOK	100 kbps	5 mW		40 mm		Neural Stimulator
[15]	≈ Rx: 112.5 λ	6.78 MHz	twd Int.: OOK twd Ext.: LSK	twd Ext.:200 kbps	120 mW	20% (max)	25 mm	Dog Shoulder	Muscolar Stimulator
[18]	Tx: 40 λ Rx: 0.4 λ	915 MHz			0.14 mW	0.06%	15 mm	Bovine Muscle	Various

[8] "T.Akin et al.," A wireless implantable multichannel digital neural recording system for a micromachined sleve electrode", IEEE J. Solid -State Clic., vol.88, pp. 109-118, jan 1998.
[9] C.Sauer et al., "Power Harvesting and Telemetry in CMOS for implanted Devices", IEEE Trans on Clic., ults and Systems, vol.52, n.12, pp. 2605-2618, 2005.

[10] B. Lenaerts et. al., "An inductive power link for a wireless endoscope", Biosensors and Bioelectronics, vol.22, pp. 1890-1895, 2007

[11] K.M. Silay et.al., "Load Optimization of an inductive Power Link for Remote Powering of Biomedical Implants", IEEE Proc. of International Symposium on Circuits and Systems 2009, pp. 588-586, May 2009.

[12] B. Lenserts et. al., "An inductive power system with integrated bi-directional data-transmission", Sensors and Actuators A, vol. 115, pp.2 21-229, 2004

[18] J. Parramon et al., "ASIC -based battery less implantable telemetry microsystem for recording purposes", Eng. In Necl. 2 Microsoft Bio. Soc., in Proc. of the 19th Annual Int. Conf., vol.5, pp. 2225-2228, 1997.

[14] G. Gud na son et al., "A Chip for an implaintable Neural Stimulator", Analog Integrated Circuits and Signal Processing , vol.22, pp.81–89, 1999

[15] B. Smithet al., "An externally powered, multichannel, implantable stimulator-telemeter for control of paralyzed muscle", IEEE Thans. on Biomed. Eng., vol.4.5, p. 468-475, 1998. [18] A.S.Y. Poon et al., "A mm-sized implantable Power Receiver with Adaptative Link Compensation", Stanford University



The Tiny Spiral Inductors



J. Olivo et al./Microelectronic Engineering 113 (2014) 130–135

Two versions of the antenna have been fabricated and tested

The Tiny Spiral Inductors on Air



Two versions of the antenna have been fabricated and tested

The Multi-layer Inductor on Tissue





J.Olivo, S. Carrara, G.Demicheli / IEEE TBCAS 2013

2.09 mW (25mm – Bovine Tissue) - THD 2.08%

3.6 mW (14mm – Bovine Tissue) - THD 2.27%

Communication is achieved at 100 kbps

Data Transmission



The Patch Design



The Realized Remote Powering Patch



The patch has been realized with off-the-shelf components

The Android interface



The Bluetooth[®] Interface for android smartphones as well as for iPads has been already developed



20 March 2013 Last updated at 01:49 GMT

4.3K K Share

'Under the skin' blood-testing device developed

By Michelle Roberts

Health editor, BBC News online

Scientists say they have developed a tiny blood-testing device that sits under the skin and gives instant results via a mobile phone.

The Swiss team say the wireless prototype half an inch (14mm) long - can simultaneously check for up to five different substances in the blood.

The data is sent to the doctor using radiowaves and Bluetooth technology.



The device sits under the skin and takes multiple readings

Biocompatible Packaging



The Biocompatible Integration



Already tested in animal models
Biocompatibility tests on mice



(c) S.Carrara, EPFL (Switzerland)







Tests of inflammation induced in mouse by the implanted Bio-Nano-Sensor and the wear remote system

(c) S.Carrara, EPFL (Switzerland)



- P450 Cytochromes are required to detect Exogenous metabolites (Drugs)
- Oxidases are required to detect endogenous metabolites (bio-markers)
- Carbon Nanotubes are definitely required to improve sensitivity of molecular detection
- Dedicated CMOS design is required for a reliable electrochemical sensing of human metabolites
- Remote Powering is required for minimally invasive Under-the-Skin Devices
- Telemetry of human metabolism on our smartphones is actually feasible

Conclusion: Learning to Hate Big Tech



By TIME, May 14, 2012

By being more corporate and less cool, IT firms are becoming as popular as banks

(c) S.Carrara, EPFL (Switzerland)

Thanks to:

- Andrea Cavallini
- Camilla Bai-Rossi
- Cristina Boero
- Sara Ghoreishizadeh
- Daniel Torre
- Daniela De Venuto
- Irene Taurino
- Arnaud Magrez
- Dino Giuseppe Albini
- Victor Erokhin
- Jacopo Olivo
- Onur Kazanç
- Enver Gürhan Kilinç
- Catherine Dehollain
- Maaike Op de Beeck
- Giovanni De Micheli



Thank you for your attention!



Coordinates

Sandro Carrara Ph.D EPFL - Swiss Federal Institute of Technology in Lausanne - Switzerland

Web: http://si2.epfl.ch/~scarrara/ email: sandro.carrara@epfl.ch